What “Heart Safe” Means for an Oral GLP-1
A headline about a new diabetes medicine being “heart safe” can sound like a simple answer: the drug protects the heart. Clinical trials often mean something more precise. A new study of oral orforglipron, marketed as Foundayo for its current U.S. weight-management indication, found that it was noninferior to insulin glargine for a defined group […]
Tirzepatide and Cardiovascular Risk: What New Evidence—and the Updated Mounjaro Label—Mean for Type 2 Diabetes Care
Tirzepatide, sold as Mounjaro for type 2 diabetes in the United States, has become a major part of the public conversation about diabetes and metabolic health. Recent reporting has focused on two related developments: a large real-world study linking tirzepatide with fewer major cardiovascular events than a cardiovascular-neutral comparison medicine, and a new Mounjaro indication […]